Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial

医学 易普利姆玛 无容量 内科学 胰腺癌 肿瘤科 无进展生存期 养生 化疗 癌症 维持疗法 临床研究阶段 封锁 外科 胃肠病学 免疫疗法 受体
作者
Kim A. Reiss,Rosemarie Mick,Ursina Teitelbaum,Mark H. O’Hara,Charles Schneider,Ryan Massa,Thomas B. Karasic,Rashmi Tondon,Chioma Onyiah,Mary Kate Gosselin,Alyssa Donze,Susan M. Domchek,Robert H. Vonderheide
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (8): 1009-1020 被引量:71
标识
DOI:10.1016/s1470-2045(22)00369-2
摘要

Background Establishing alternatives to lifelong chemotherapy for patients with advanced pancreatic cancer has been proposed to address chemotherapy resistance and cumulative toxicity. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in this setting, and concurrent immune checkpoint blockade could offer synergistic tumour control. The aim of this study was to test the safety and antitumour activity of maintenance with PARP inhibition combined with immune checkpoint blockade in patients with advanced pancreatic cancer who had a stable response to platinum-based chemotherapy. Methods We conducted an open-label, randomised, phase 1b/2 study of niraparib plus anti-PD-1 (nivolumab) or anti-CTLA-4 (ipilimumab) therapy for patients with advanced pancreatic cancer whose cancer had not progressed after at least 16 weeks of platinum-based therapy. Patients were randomly assigned (1:1) via permuted block randomisation (block sizes 2 and 4) to niraparib 200 mg orally per day plus either nivolumab 240 mg intravenously every 2 weeks (later changed to 480 mg intravenously every 4 weeks based on manufacturer update) or ipilimumab 3 mg/kg intravenously every 3 weeks for four doses. The primary endpoints were safety and progression-free survival at 6 months. Treatment groups were not compared for activity, which was assessed in each group against a clinically meaningful progression-free survival at 6 months of 44% (null hypothesis). Superiority of a treatment regimen could be declared if 6-month progression-free survival was 60%, and inferiority if 6-month progression-free survival was 27%. All patients who received at least one dose of study treatment and had at least one post-treatment assessment of response according to Response Evaluation Criteria in Solid Tumours version 1.1 were included in the efficacy population. The safety population consisted of all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03404960, and enrolment is completed and follow-up is ongoing. Findings 91 patients were enrolled between Feb 7, 2018, and Oct 5, 2021 and were randomly assigned to niraparib plus nivolumab (n=46) or niraparib plus ipilimumab (n=45). Of these patients, 84 were evaluable for the progression-free survival endpoint (niraparib plus nivolumab=44; niraparib plus ipilimumab=40). Median follow-up was 23·0 months (IQR 15·0–31·5). 6-month progression-free survival was 20·6% (95% CI 8·3–32·9; p=0·0002 vs the null hypothesis of 44%) in the niraparib plus nivolumab group; and 59·6% (44·3–74·9; p=0·045) in the niraparib plus ipilimumab group. Ten (22%) of 46 patients in the niraparib plus nivolumab group and 23 (50%) of 45 patients in the niraparib plus ipilimumab group had a grade 3 or worse treatment-related adverse event. The most common grade 3 or worse adverse events in the niraparib plus nivolumab group were hypertension (in four [8%] patients), anaemia (two [4%]), and thrombocytopenia (two [4%]) whereas in the niraparib plus ipilimumab group these were fatigue (in six [14%]), anaemia (five [11%]), and hypertension (four [9%]). There were no treatment-related deaths. Interpretation The primary endpoint of 6-month progression-free survival was met in the niraparib plus ipilimumab maintenance group, whereas niraparib plus nivolumab yielded inferior progression-free survival. These findings highlight the potential for non-cytotoxic maintenance therapies in patients with advanced pancreatic cancer. Funding Bristol Myers Squibb, GlaxoSmithKline, the Basser Center Young Leadership Council, The Konner Foundation, The Pearl and Philip Basser Innovation Research Award, the Anonymous Foundation, and the US National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吴家辉发布了新的文献求助10
刚刚
刚刚
猪猪hero应助LS采纳,获得10
1秒前
1秒前
1秒前
1秒前
2秒前
可靠紫青完成签到,获得积分10
2秒前
2秒前
奇凌完成签到,获得积分10
2秒前
2秒前
酷波er应助yewungs采纳,获得10
2秒前
3秒前
大模型应助可爱的天曼采纳,获得10
3秒前
又日新发布了新的文献求助10
3秒前
4秒前
4秒前
4秒前
1724986014发布了新的文献求助10
5秒前
5秒前
5秒前
斯文败类应助mayberichard采纳,获得10
6秒前
6秒前
Fin2046发布了新的文献求助10
6秒前
7秒前
刘步遥完成签到 ,获得积分10
7秒前
初余发布了新的文献求助10
8秒前
朝暮应助难过千易采纳,获得10
8秒前
8秒前
wjx发布了新的文献求助10
8秒前
8秒前
smottom应助莫愁采纳,获得20
8秒前
Gnor发布了新的文献求助10
9秒前
冬去春来发布了新的文献求助10
9秒前
平常的铃铛完成签到,获得积分10
10秒前
11秒前
11秒前
爆米花应助韩凡采纳,获得10
11秒前
QZZ关闭了QZZ文献求助
11秒前
lyric发布了新的文献求助20
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975165
求助须知:如何正确求助?哪些是违规求助? 3519595
关于积分的说明 11198781
捐赠科研通 3255912
什么是DOI,文献DOI怎么找? 1798001
邀请新用户注册赠送积分活动 877343
科研通“疑难数据库(出版商)”最低求助积分说明 806298